메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

MagMutualがAppianで業務改革

AppianのAIを活用したプラットフォームで保険契約の移行時間を削減見積り速度を向上させ業務運用を統一米バージニア州MCLEAN, 2025年8月28日 -- Appian (NASDAQ: APPN) は本日、 MagMutual社がAppianのAIを活用したプラットフォームを使って業務オペレーションの変革を成功させたことを発表しました。MagMutualは、全米4万以上の医療機関や組織に総合的な保険を提供する、医療過誤保険のリーディングプロバイダーです。同社はAppianやXebiaと提携し、基幹プロセスのモダナイズと保険契約者のエクスペリエンスの向上に取り組んでいます。 MagMutualは、レガシーシステムと手作業のワークフローに起因する問題に直面していました。見積りの作成に時間がかかる上、プロセスが断片化されていました。また、サイロ化されたシステムによって運用の可視性と応答性が損なわれ、買収に伴う保険契約の移行には最大3年かかったこともありました。「見積りのポータルを公開してから数時間以内に保険契約が成立し、広告を打たなくても非常に短期間で 100 万ドルの収益を達成しました」と、MagMutualの最高顧客責任者Mark Poling氏は述べています。 MagMutualは、Appianと
- 황정호 기자
- 2025-08-28 08:00
AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector

HONG KONG, Aug. 28, 2025 -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced today the release of its 2025 interim report, showcasing robust revenue growth. With major products entering the market phase, R&D costs are decreasing, and operational expenditures are being optimized. Four core innovative products are poised for commercialization, and significant advancements have been made in overseas market expansion. Two mRNA technology vaccines have simultaneously received clinical trial approvals in both the PRC and the U.S., leading to optimistic forecasts from instit
- 김갑성 기자
- 2025-08-28 07:45
Ascletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose Study

- ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison. - Higher drug exposure and favorable tolerability profile positions ASC30 oral once-daily tablet favorably compared to orforglipron. - Topline data from the Ascletis' U.S. Phase IIa study for ASC30 in participants with obesity or overweight are expected in the fourth quarter of 2025. HONG KONG, Aug. 28, 2025 -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces promising topline ph
- 김갑성 기자
- 2025-08-28 07:45
Bestqool Honors Workers With Light-Based Recovery Solutions This Labor Day

From Aug 27 through Sep 4, all Bestqool Products will be available at unbeatable prices. NEW YORK, Aug. 27, 2025 -- After long hours of daily work, the body needs more than rest — it requires a sustainable, gentle, and easy-to-maintain recovery method. Bestqool, a health and wellness technology brand for light-based recovery, is celebrating this year's Labor Day with an important message: Honor your labor by protecting the body that does the work. For a limited time, Bestqool is offering 12% off all products from August 27th to September 4th, giving workers the opportun
- 김갑성 기자
- 2025-08-27 23:31
Fangzhou Posts Strong 1H Revenue and Profit as Physician Network and User Base Expand

HONG KONG, Aug. 27, 2025 -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, reported a profitable first half of 2025, supported by an expanding user base, higher operating efficiency, and accelerated deployment of AI across its healthcare services and internal operations. Net Profit Swings to Positive as Targeted User Base Unlocks Growth Fangzhou posted revenue of RMB 1.494 billion for the six months ended June 30, up 12.9% from a year earlier. Net profit reached RMB 12.5 mill
- 김갑성 기자
- 2025-08-27 23:09
Harbour BioMed Reports 2025 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its interim results for the six months ended June 30, 2025. Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: "In the first half of 2025, Harbour BioMed achieved several significant milestones. During the reporting period, the company's pro
- 김갑성 기자
- 2025-08-27 22:40
XtalPi Holdings Announces 2025 Interim Results

SHENZHEN, China, Aug. 27, 2025 -- Key Highlights from the Financial Report: Revenue surged 404% year over year to RMB 517 million in the first half of 2025. Adjusted net profit reached RMB 141 million, marking the company's first-ever half-year profitability. XtalPi was added to the MSCI China Small Cap Index, underscoring strong recognition of its investment value by the international capital markets. Significant breakthroughs and milestones were achieved across multiple business lines. Drug Discovery Solutions: The Deep Integration of Ad
- 김갑성 기자
- 2025-08-27 22:26
XtalPi Holdings Announces 2025 Interim Results

SHENZHEN, China, Aug. 27, 2025 -- Key Highlights from the Financial Report: Revenue surged 404% year over year to RMB 517 million in the first half of 2025. Adjusted net profit reached RMB 141 million, marking the company's first-ever half-year profitability. XtalPi was added to the MSCI China Small Cap Index, underscoring strong recognition of its investment value by the international capital markets. Significant breakthroughs and milestones were achieved across multiple business lines. Drug Discovery Solutions: The Deep Integration of Ad
- 황정호 기자
- 2025-08-27 22:23
Advancing DEL Technology for the Research Lab: HitGen Introduces OpenDEL™ 5.0

Start Your Journey to Access Vast Chemical Space CHENGDU, China, Aug. 27, 2025 -- Developing new medicines demands smart technology and powerful tools. DNA-encoded library (DEL) technology, with its unique ability to rapidly screen billions of compounds to identify small molecule hits, has transformed drug discovery. HitGen Inc. is raising the bar with the introduction of OpenDEL™ 5.0 – featuring a total of 4 billion diverse compounds designed to tackle challenging biological targets. OpenDEL™ 5.0 comes in a convenient kit format that is accessible to scientists in industry and
- 김갑성 기자
- 2025-08-27 21:30
Neusoft Medical Systems Launches China's First Photon-Counting CT with NMPA Approval

SHENYANG, China, Aug. 27, 2025 -- Neusoft Medical Systems today announced that its NeuViz P10 photon-counting CT has received market approval from China's National Medical Products Administration (NMPA). This marks the first photon‑counting CT approved in China, and the world's first wide‑body system equipped with an 8‑cm detector. Photon-counting CT (PCCT) is considered a breakthrough in next‑generation imaging. Unlike conventional CT scanners, which first convert X‑rays into light before generating digital images, the NeuViz P10 uses a cadmium zinc telluride (CZT) detector t
- 김갑성 기자
- 2025-08-27 21:03

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-30_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 30일 17시 20분